Quick Answer
ARS Pharmaceuticals, Inc. reported Common Stock Shares Outstanding of 99.29 million shares for the year ending 2025.
- ARS Pharmaceuticals, Inc. showed an increase of +1.4% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from ARS Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: 34.83 million shares | Q2 2021: 34.96 million shares | Q3 2021: 35.04 million shares | Q1 2022: 35.12 million shares | Q2 2022: 35.17 million shares | Q3 2022: 35.88 million shares | Q1 2023: 94.45 million shares | Q2 2023: 95.32 million shares | Q3 2023: 95.80 million shares | Q1 2024: 96.57 million shares | Q2 2024: 96.94 million shares | Q3 2024: 97.15 million shares | Q1 2025: 98.13 million shares | Q2 2025: 98.70 million shares | Q3 2025: 98.84 million shares.
- Over the full 6 years of available data (2020 to 2025), ARS Pharmaceuticals, Inc.'s Common Stock Shares Outstanding has grown by 186.1%.
- Historical annual values: Fiscal year 2025: 99.29 million shares | Fiscal year 2024: 97.95 million shares | Fiscal year 2023: 96.41 million shares | Fiscal year 2022: 93.94 million shares | Fiscal year 2021: 30.37 million shares | Fiscal year 2020: 34.70 million shares.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: